Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS

Cnbx Pharmaceuticals Inc. CNBX

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
▼ 100.0% YoY
$-313,976

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -0.3
0.5M1.0M-3.0M-6.0M
2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2024 · Operating -448.3% · Net -534.5%
-20000%-40000%
200720162025
ROE
FY2022 · ROE -216.6%
-100%-200%
200720162025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks

Total assetsUSD 18,437.00
EquityUSD -2.5M
CashUSD 15,111.00
Current ratio0.01×

Equity funds -13540% of total assets.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CNBX, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B0.00.00.00.00.00.00.00.00.00.00.0◌◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌
Income tax $B◌◌◌◌◌◌◌◌◌◌0.00.00.0◌◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.00−0.02−0.42−3.59−0.02−0.100.02−0.03−0.020.00−0.01−0.01−0.040.00−0.16−0.17◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %———−216.6−178.9−90.513.0————————−97.9−49.4−9.0−7.3
Shares out B0.550.030.020.000.150.140.130.120.120.110.100.100.00◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 58 reconciliationsAUDITED

Reconciled in 17 of the 19 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsAugust 31
SEC categoryemerging growth company
Data on record since2007

Share this section

Download image